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                                   ABSTRACT 
  Background      Since initial approval for the treatment of 
rheumatoid arthritis (RA), rituximab has been evaluated 
in clinical trials involving various populations with RA. 
Information has also been gathered from registries. This 
report therefore updates the 2007 consensus document 
on the use of rituximab in the treatment of RA.   
  Methods      Preparation of this new document involved 
many international experts experienced in the treatment 
of RA. Following a meeting to agree upon the core 
agenda, a systematic literature review was undertaken 
to identify all relevant data. Data were then interrogated 
by a drafting committee, with subsequent review and 
discussion by a wider expert committee leading to the 
formulation of an updated consensus statement. These 
committees also included patients with RA.   
  Results      The new statement covers wide-ranging issues 
including the use of rituximab in earlier RA and impact on 
structural progression, and aspects particularly pertinent 
to rituximab such as co-medication, optimal dosage 
regimens, repeat treatment cycles and how to manage 
non-response. Biological therapy following rituximab 
usage is also addressed, and safety concerns including 
appropriate screening for hepatitis, immunoglobulin 
levels and infection risk. This consensus statement will 
support clinicians and inform patients when using B-cell 
depletion in the management of RA, providing up-to-date 
information and highlighting areas for further research.   
  Conclusion      New therapeutic strategies and treatment 
options for RA, a chronic destructive and disabling 
disease, have expanded over recent years. These have 
been summarised in general strategic suggestions and 
speciﬁ  c management recommendations, emphasising the 
importance of expedient disease-modifying antirheumatic 
drug implementation and tight disease control. This 
consensus statement is in line with these fundamental 
principles  of  management.         
  A recent advance in rheumatoid   arthritis (RA) 
has been the introduction of B-cell depletion as 
a therapeutic modality. Rituximab, a chimeric 
anti-CD20 monoclonal antibody is the currently 
available, licensed B-cell depleting agent, with 
several studies supporting the efﬁ  cacy and accept-
able safety proﬁ  le of this approach.    1       –       3      To address 
the beneﬁ  ts, limitations and safety concerns of its 
application, a consensus statement on the use of 
rituximab in patients with RA was formulated in 
2006.    4    Since then a large amount of new informa-
tion has become available, with new insights into 
both the efﬁ  cacy and the safety of B-cell depletion 
with rituximab. 
  Therefore, an international group of experts and 
patient representatives mainly from Europe expe-
rienced in clinical research, the use of biological 
agents and the development of recommendations, 
convened in Amsterdam in May 2010 to revise the 
consensus statement. The members of the original 
expert group were re-invited to participate and, in 
addition, more recent contributors to the ﬁ  eld pri-
marily based on the original publication. The steer-
ing group, consisting of MHB, JSS and PE had full 
control over the invitations. 
  This update will concern the following areas: 
      ▶   Mode of action 
      ▶   Indication, considerations and screening for initi-
ating rituximab in RA 
      ▶   Treatment dose algorithm and co-medication 
      ▶   Evaluation and management of response as 
well as lack of response and considerations for 
retreatment 
      ▶   Predictive factors of response 
      ▶   Contraindications and adverse events (AE) 
      ▶   Long-term exposure—efﬁ  cacy and safety issues 
      ▶   Research agenda 
      Importantly, we have on this occasion placed 
greater emphasis on the patient perspective. 
  To achieve our objective, a systematic literature 
review of the published literature on the efﬁ  cacy 
and safety of rituximab in treating patients with 
RA was ﬁ  rst undertaken (MHB) to identify relevant 
data and information (details included in the sup-
plementary material, available online only). 
  The outcome of the discussion of the new data 
and results of this activity will be presented in this 
publication. Categories of evidence will be indicated 
next to each reference in line with published guide-
lines (Table 1);    5    assignment of the Ia category was 
agreed to require the availability of two or more ran-
domised controlled trials (RCT) with similar results. 
  Signiﬁ  cant amounts of data have been generated 
and discussed, all of which could not be included 
within this document but have instead been added 
in the supplementary material available online 
only. 
    MECHANISM OF ACTION OF RITUXIMAB IN RA 
  Rituximab targets the CD20 molecule, which is 
expressed on the surface of B cells from pre-B-cell 
through memory B-cell stages    6        7    but not on stem 
For numbered afﬁ  liations see 
end of article.
  ▶  Supplementary material is 
published online only. To view 
these ﬁ  les please visit the 
journal online (  http://ard.bmj.
com ). 
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patients, the duration of the response to a single course of ritux-
imab usually lasts more than 6 months    22    (category Ib). Recent 
phase III studies have also expanded information on the efﬁ  cacy 
of rituximab in methotrexate inadequate responders (‘MIRROR’ 
and ‘SERENE’ studies)    23        24    and addressed methotrexate-naive 
patients (‘IMAGE’ study).    25    Response rates in the former stud-
ies demonstrated the superiority of rituximab over placebo. In 
the IMAGE study involving methotrexate-naive patients, ritux-
imab plus methotrexate was superior in clinical and functional 
outcomes to methotrexate alone; there was also a signiﬁ  cant 
reduction in radiographic progression versus methotrexate 
monotherapy after 6, 12 and 24 months.    25    Inhibition of struc-
tural damage progression had already been shown previously 
in patients with previous inadequate response to TNF inhibitors 
treated with methotrexate and rituximab, and this effect was 
sustained after 2 years (category Ib).    26        27    
  The wider use of rituximab has meant a better apprecia-
tion of the associated safety issues with, in particular, focus on 
infection risk. The oncology literature has highlighted concerns 
over hepatitis B reactivation.    28        29    In addition, more speciﬁ  c con-
sequences of B-cell depletion, namely low baseline IgG levels 
and the observation of subsequent greater infection risk has 
indicated the value of checking IgG levels before administering 
rituximab.    30    
  In addition to data from clinical trials on the efﬁ  cacy and safety 
of rituximab, drug registries may provide information that is 
complementary to information from the trials. Registries include 
patients with severe comorbidities that contraindicate the use 
of, for example, TNF inhibitors, as well as patients treated with 
rituximab without the previous use of other biological agents 
and/or receiving rituximab as monotherapy.    31        32    
   RECOMMENDATIONS 
  Indication 
  At present, in line with the current licensed indication, rituximab 
may be used in adult patients with RA who qualify for treatment 
with biological agents and have had an inadequate response or 
intolerance to one or more TNF inhibitors    33   ; patients with a con-
traindication to TNF inhibitors have not yet been adequately 
studied. However, registry and non-interventional studies have 
reported 17–20.5% of patients receiving rituximab as their ﬁ  rst 
biological disease-modifying antirheumatic drug (DMARD).    30        34    
Before concluding that a patient has not responded to a TNF 
inhibitor, attempts should be made to improve the ongoing regi-
men by optimising the DMARD or TNF inhibitor treatment,    35    
considering respective recommendations. The SERENE and 
MIRROR studies (described later) conﬁ  rm efﬁ  cacy in a meth-
otrexate-inadequate responder/TNF inhibitor-naive population 
and the IMAGE study in methotrexate-naive patients.    23       –       25    
cells and pro B cells nor on plasma cells/blasts. Rituximab leads 
to transient but almost complete depletion of B cells in the blood 
and only partial depletion in the bone marrow    8       –       13    and synovial 
tissue.    14       –       16    Response has been shown to correlate with the level 
of synovial membrane B-cell depletion    9    and early peripheral 
blood depletion of B cells measured by sensitive assays,    9    pos-
sibly useful as a surrogate. It also frequently induces a reduction 
of immunoglobulins, notably IgM    17        18    (see supplementary mate-
rial, available online only, for more detailed discussion). 
  B-cell repopulation studies following rituximab treatment 
suggest reconstitution with antigenically inexperienced, transi-
tional B cells derived from an immature population.    8        19    In some 
patients, B-cell repopulation leads to a relapse of the disease. 
However, further investigations to be able to clarify clear pat-
terns predictive of relapse are still needed. 
   BACKGROUND 
  Rituximab is licensed and well established for patients with 
non-Hodgkin’s lymphoma. Rituximab has also been approved 
by the US Food and Drug Administration and by the European 
Medicines Agency in Europe for the treatment of patients with 
RA who have had an inadequate response or were intolerant 
to tumour necrosis factor (TNF) inhibitors. In these patients, 
according to the licence, rituximab is given intravenously as two 
1 g infusions (with intravenous glucocorticoid premedication; 
  table 2  ), separated by 2 weeks, with concomitant methotrex-
ate.    2        3    Worldwide, more than 100 000 patients have received 
rituximab to date for RA.    20        21    
    In earlier studies, rituximab has shown efﬁ  cacy when used 
alone (category Ib) and in combination with other agents, includ-
ing methotrexate    1    (category Ia). The efﬁ  cacy and durability of 
monotherapy is less than that of combination treatment with 
methotrexate (category Ib). Subsequent studies on rituximab 
in combination with methotrexate have proved to be success-
ful in markedly reducing inﬂ  ammatory activity and increasing 
functional ability and quality of life    3    (category Ia). In responding 
  Table  2         Doses of rituximab and glucocorticoids in six randomised controlled clinical trials   
 Study   Rituximab  dose   Intravenous  glucocorticoid   Oral  glucocorticoid 
Edwards   et al   1    (MTX-IR) 2×1000 mg 2×100 mg MP on days 1 and 15 60 mg P days 2, 4–7 + 30 mg P days 8–14
Emery   et al   2    (DANCER) (MTX±TNF-IR) 2×1000 mg or 2×500 mg (1) 0  (1) 0
(2) 2×100 mg MP (2) 0
(3) 2×100 mg MP (3) 60 mg P days 2–7 + 30 mg P days 8–14
Cohen   et al   3    (REFLEX) (TNF-IR) 2×1000 mg 2×100 mg MP 60 mg P days 2–7 + 30 mg P days 8–14
Tak   et al   25    (IMAGE) (MTX-naive) 2×1000 mg or 2×500 mg 2×100 mg MP  
Rubbert-Roth   et al   23    (MIRROR) (MTX-IR) 2×1000 mg or 2×500 mg or 1×1000 mg and 1×500 mg 2×100 mg MP  
Emery   et al   24    (SERENE) (MTX-IR) 2×1000 mg or 2×500 mg 2×100 mg MP  
      No marked difference in efﬁ  cacy between the two rituximab doses.   2      31    –    33    IMAGE: 2×1000 mg associated with structural retardation ﬁ  rst 24 weeks; maintenance with both rituximab 
doses week 24 to 2 years. Premedication associated with reduced infusion-related events infusion one; minimal difference for infusion two. 
  IR, inadequate-responder; MP, methylprednisolone; MTX, methotrexate; P, prednisolone; TNF, tumour necrosis factor.       
  Table  1      Evidence  hierarchy   
 Category  of 
evidence    Type of study 
Ia Meta-analyses of RCT or RCT ≥1 result
Ib RCT
IIa Controlled study without randomisation
IIb Quasi-experimental study
III Non-experimental descriptive studies such as comparative, correlation 
and case–control studies
IV Expert committee reports or opinion or clinical experience of respective 
authorities, or both
   Modiﬁ   ed  from  Shekelle   et al.5   
  RCT, randomised controlled trial.     
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should thus have active disease in line with inclusion in clinical 
trials, deﬁ  ned as at least moderate disease activity by composite 
scores, such as by the 28-joint disease activity score (DAS28, 
>3.2), the simpliﬁ  ed disease activity index (SDAI, >11), the clini-
cal disease activity index (CDAI, >10) or similar measures.    48        49    
  So far, in the phase II and phase III studies of TNF inhibitor 
failure patients, rituximab was started as soon as 4 weeks after 
the last dose of etanercept and 8 weeks after the last dose of inf-
liximab or adalimumab. Exclusion criteria comprised evidence 
of major systemic involvement due to RA, other major illnesses 
or laboratory abnormalities, and a history of recurrent relevant 
infections.    2        3    
  Patients treated in real life are more heterogeneous than in 
RCT with regard to comorbidities, disease activity as well as 
previous and concomitant use of other medications; informa-
tion from drug registries, therefore, provides additional impor-
tant insights.    34        50        51    
   Screening  before  initiating  rituximab 
  Initiation of rituximab should be preceded by recording a 
detailed history (regarding chronic or recent comorbidity, such 
as cardiovascular and pulmonary diseases, recurrent infections 
and allergies) and a complete physical examination to con-
sider possible contraindications in all patients, especially the 
older patient. Special attention should be paid to vaccinations. 
Patients should be well informed of the full therapeutic proﬁ  le 
of rituximab, including all risks and beneﬁ  ts. 
  In clinical trials on rituximab, patients with RA have been 
prescreened for hepatitis B and C; patients testing negative for 
hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg), but 
positive for antibodies against hepatitis B core (HBc) antigen 
were allowed rituximab therapy if negative for HBV DNA. While 
cases of HBV reactivation are widely described in the oncology 
literature, only one case report of HBV reactivation in a patient 
with RA treated with rituximab    52    has been reported. Data from 
patients with RA as well as from the oncology and hepatology 
literature are discussed in the supplementary material, available 
online only. The risk of hepatitis C virus is in contrast, unclear 
with conﬂ  icting data and perspectives on the possible conse-
quences of rituximab and chemotherapy generally.    53        54    
  As always, the individual risk–beneﬁ  t ratio should be evaluated 
and discussed with the patient. Management of such patients 
should be in consultation with an expert   gastroenterologist/
hepatologist. Expert advice is that serological markers of HBV 
infection should be obtained before starting treatment. As dis-
cussed in the supplementary material (available online only), 
reactivation has been documented in HBsAg-negative as well as 
HBsAg-positive patients,    28        29    stressing the importance of mea-
suring not only HBsAg but also antibodies against HBc antigen 
to identify positive carrier status. HBsAg negativity (with also 
anti-HBs antibody negativity) identiﬁ   es those requiring vac-
cination before immunosuppressive therapy. HBV DNA titres 
are not indicated for screening, rather assessment of viral load 
and response in established chronic HBV infection. Several 
recommendations have been published including those by the 
Centers for Disease Control and Prevention, although they 
partly differ.    55   –    57    Nevertheless, patients who are HBsAg posi-
tive and/or anti-HBc positive should be treated prophylactically. 
The management of occult HBV infection with anti-HBc posi-
tivity alone remains unclear; in such patients HBV DNA could 
be determined and then prophylactic therapy considered; if 
not undertaken, close follow-up to detect a rise in HBV DNA 
is recommended. Routine testing for hepatitis C should also be 
considered. A recent review paper and editorial advise a similar 
  Current evidence on the efﬁ  cacy of rituximab relates primar-
ily to rheumatoid factor (RF) positive patients    1        2    (category Ia). 
While in the phase III (REFLEX) study on TNF inhibitor non-
responders, a response was seen in RF-negative patients,    3    other 
substudy analyses on RF-negative patients showed that the 
response in this population was not signiﬁ  cantly different from 
placebo-treated patients.    2        36    Indeed, in the ﬁ  rst of these stud-
ies (REFLEX), protection from joint damage was only evident in 
seropositive patients.    37    
  Recently, pooled data from two phase III studies in methotrex-
ate-inadequate responder populations as well as a substudy from 
the IMAGE study that evaluated methotrexate-naive patients 
have all reinforced the view that seropositive patients (anti-cit-
rullinated peptide antibody (ACPA), RF or both) demonstrate a 
more robust response to rituximab    25        38    (  table 3  ; data discussed in 
the supplementary material available online only). In the IMAGE 
study,    25    there was evidence of signiﬁ  cantly greater joint protec-
tion in the seropositive subpopulation treated with rituximab and 
methotrexate; while in the seronegative group, inhibition of pro-
gression of damage in each treatment group was comparable and 
generally low even in the placebo/methotrexate group. Superior 
efﬁ  cacy has also been demonstrated in drug registries for patients 
who were RF and/or ACPA positive    39       –       42    when compared with 
the seronegative patient group. Another study (discussed further 
in the supplementary material available online only) identiﬁ  ed 
the four best potential biomarkers from the REFLEX study (that 
included IgA RF and IgG anti-CCP3) and applied these, together 
with IgM and IgG isotypes of RF to the SERENE study; the 
presence of any RF isotype or IgG ACPA was associated with a 
higher American College of Rheumatology (ACR50) response.    43    
A multivariate analysis from a single-centre study suggested RF 
(and not ACPA), low disability and the previous number of TNF 
inhibitors as predictive of response to rituximab.    44    Therefore, 
while one randomised trial suggested efﬁ  cacy for rituximab in 
seronegative patients, data from the other trials described above, 
together with descriptions of a more unpredictable safety proﬁ  le 
in these patients,    45    suggest it would perhaps be more appropriate 
for alternative treatment approaches to be considered. 
    Considerations  for  initiating  treatment 
  Before treatment, an individual therapeutic goal should be estab-
lished as a shared decision between each patient and the treating 
physician. The doctor should be experienced in the diagnosis 
and treatment of RA, including the use of biological DMARD 
agents. The general principles should follow published recom-
mendations.    46        47    Patients considered for treatment generally 
  Table  3      Pooled  analysis  38    of response rates for autoantibody positive 
and negative patients from the MIRROR   23    and SERENE   24    studies  
 
 Week  24   Week  48 
 Seropositive   Seronegative   Seropositive   Seronegative 
ACR responses (n) 514 106 506 101
ACR20 (%) 62.3* 50.9 71.1* 51.5
ACR50 (%) 32.7* 19.8 44.9** 22.8
ACR70 (%) 12.1 5.7 20.9* 6.9
EULAR outcomes (n) 507 105 496 101
EULAR response (%) 74.8* 62.9 84.3* 72.3
Mean change DAS28 −1.97** −1.50 −2.48*** −1.72
DAS28 categories (n) 510 105 499 101
Low disease (%) 16.9 10.5 26.5* 12.9
DAS28 remission (%) 10.6 4.8 13.2 5.9
      *p<0.05, **p<0.001, ***p<0.0001 vs seronegative. 
  ACR, American College of Rheumatology; DAS28, disease activity score 28; EULAR, 
European League Against Rheumatism.     
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(below the lower limit of normal) should be considered with cau-
tion (see also section on ‘Immunoglobulins and infection risk’). 
  In clinical trials, B-cell levels have been measured, but the util-
ity of these measurements in routine practice is not conﬁ  rmed. 
   Vaccination 
  Some data from the oncology literature indicate that in patients 
receiving rituximab, response to vaccination may be ineffective.    62    
Patients with RA receiving rituximab have been investigated for 
their response to vaccination in two studies, one of which was 
a RCT    63        64    (discussed in the supplementary material, available 
online only). Any patient considered for rituximab therapy should 
receive all indicated vaccines (hepatitis B for at-risk population, 
pneumococcus, tetanus toxoid every 10 years, inﬂ  uenza annu-
ally) before treatment. Ideally, vaccination should be undertaken 
at least 4 weeks before rituximab therapy. More data are needed 
on the potential risk of vaccination with live vaccines, which 
are therefore not recommended for rituximab-treated patients. 
European League Against Rheumatism (EULAR) recommenda-
tions on vaccination provide additional guidance for patients with 
rheumatological diseases treated with biological agents.    65    
   Treatment  dose  and  co-medication 
  Treatment  dosage 
  In patients who have received previous TNF inhibitor treat-
ment, rituximab use is licensed at a dose of 1000 mg per infu-
sion on days 1 and 15.    3    Rituximab showed signiﬁ  cant efﬁ  cacy 
approach with a call for revision of ACR guidelines with, in 
addition, a recent publication of a provisional clinical opinion 
from the American Society of Clinical Oncology.    58       –       60    
  Chest radiography was also carried out in the clinical trials. 
Patients who did not respond to TNF inhibitor treatment will 
also have been prescreened for the presence of active or latent 
tuberculosis. In the RA clinical trials on rituximab before TNF 
inhibitor, patients with active tuberculosis were excluded, but 
patients were not screened for latent tuberculosis by any testing. 
The fact that rituximab is administered in RA with two pulses of 
glucocorticoid may by itself contribute to the risk of reactivation 
of tuberculosis.    61    However, there is no evidence of an increased 
frequency of tuberculosis in patients with lymphoma treated 
with rituximab    62    and, therefore, at this time there is no evidence 
indicating the necessity to screen patients systematically for 
tuberculosis before using rituximab in those with RA. 
  Apart from routine laboratory tests usually performed in 
patients with RA before initiating new treatments, baseline Ig 
levels should be determined, as a reduced baseline level of IgG is 
a risk factor for severe infections with rituximab;    30    in addition, 
decreased levels of IgM and IgA have been observed with ritux-
imab over time    18    (category Ia). Monitoring the IgG level at base-
line before each rituximab cycle and longitudinally is therefore 
advised, with patients particularly at risk, such as those showing 
reduced IgG levels at baseline or indeed other higher risk groups 
such as older people, requiring particularly close monitoring of 
levels and vigilance for infections. On all these grounds, ritux-
imab treatment in RA patients with hypogammaglobulinaemia 
  Table  4         Summary of response rates in the six key randomised controlled studies evaluating rituximab and methotrexate   
 Study   Response  measure 
 6  Months   12  Months 
  Plc + MTX 
  RTX (2×500 mg) 
+ MTX 
  RTX (2×1000 mg) 
+ MTX    Plc + MTX 
  RTX (2×500 mg) 
+ MTX 
  RTX (2×1000 mg) 
+ MTX 
MTX-naive
 IMAGE   25    (n=755) ACR 20
ACR 50
ACR 70
EULAR (mod+good)
DAS28 Rem
64.3
41.8
24.9
71.1
12.6
76.7
59.4
42.2
82.3
25.4
80.0
64.8
46.8
86.0
30.5
    
MTX-IR
 Phase  IIa   1    (n=80) ACR 20
ACR 50
ACR 70
EULAR (mod+good)
DAS28 Rem
38.0
13.0
5.0
 73.0
43.0
23.0
20.0
 5.0
 0
 65.0
35.0
15.0
 SERENE   24    (n=512) ACR 20
ACR 50
ACR 70
EULAR (mod+good)
DAS28 Rem
23.3
9.3
5.2
50.0
4.0
54.5
26.3
9.0
82.0
16.0
50.6
25.9
10.0
87.0
16.0
 55.7
32.9
12.6
89.0
15.0
57.6
34.1
13.5
81.0
19.0
   MIRROR   72    (n=227; excludes 
dose escalation group)
ACR 20
ACR 50
ACR 70
EULAR (mod+good)
DAS28 Rem
       64.0
39.0
20.0
73.0
9.0
72.0
48.0
23.0
89.0
19.0
MTX±TNF-IR
 DANCER   2    (n=465) ACR 20
ACR 50
ACR 70
EULAR (mod+good)
DAS28 Rem
28.0
13.0
5.0
37.0
55.0
33.0
13.0
73.0
54.0
34.0
20
67.0
    
TNF-IR
 REFLEX   3   ACR 20
ACR 50
ACR 70
EULAR (mod+good)
DAS28 Rem
18.0
5.0
1.0
20.0
0
  51.0
27.0
12.0
50.0
9.0  
   
      ACR, American College of Rheumatology; DAS28, disease activity score 28; EULAR, European League Against Rheumatism; IR, inadequate-responder; mod, moderate; MTX, 
methotrexate; Plc, placebo; Rem, remission; RTX, rituximab; TNF, tumour necrosis factor.     
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although given the availability of safer and more effective alter-
natives, in patients with RA at least, this expert group felt that 
cyclophosphamide is unnecessary as a co-medication. 
      Rituximab administration and glucocorticoid premedication 
  To reduce the frequency and severity of infusion reactions, 
patients should receive 100 mg methylprednisolone intrave-
nously before rituximab infusions (category Ib). This is particu-
larly indicated before the ﬁ  rst infusion and can also be given 
before the second infusion of each cycle, although the indica-
tion may not be as strong for the latter.    2        68    Paracetamol and 
antihistamines may be required, and although they have been 
used for premedication in all clinical trials on RA, there is no 
clear evidence from these that antihistamines should be used 
systematically. 
    Evaluation  and  management  of  response/non-response 
  Response  assessment 
  Routine rheumatological assessments should be performed 
at baseline and periodically according to standards of care for 
therapies with biological agents and methotrexate. Response to 
rituximab should be assessed by validated composite measures 
of disease activity (eg, the DAS28, SDAI or CDAI);    48    functional 
assessment (health assessment questionnaire), and evaluation of 
radiographic progression further complement the use of these 
scores. At least a low disease activity range (DAS28 ≤3.2, SDAI 
<11 or CDAI <10) and a maximisation of functional ability and 
quality of life should be the target to aim for with regard to a 
desirable disease state.    49    
   Response  proﬁ   le 
  Rituximab has a more distinctive response proﬁ  le in that the 
onset of action of rituximab is slower than that of the other bio-
logical DMARD. Furthermore, it should be noted that intrave-
nous glucocorticoid premedication will produce an early, albeit 
a usually transient, response before 8 weeks. It is important that 
this is communicated to the patient. A patient should be regarded 
as a responder if the response criteria are met after an observa-
tion period of at least 16 weeks from the initiation of treatment 
according to the recommended dosing schedule. Indeed, in most 
patients, a response (ie, some degree of improvement in disease 
activity) is usually seen by 16 weeks after the ﬁ  rst infusion    1       –       3    
(category Ia). Rituximab usually leads to rapid B-cell depletion    1       –       3    
(category Ia). 
   Considerations  for  repeated  treatment 
  Repeated treatment should be considered after at least 24 weeks 
(category IV). In line with the ‘treat-to-target’ and EULAR RA 
management recommendations,    46        47    this should be considered 
in patients who do not reach remission (exhibiting a DAS28 
≥2.6, SDAI >3.3 or CDAI >2.8)    49    or at least low disease activity 
(although with consideration of alternative targets if individual 
factors make it unlikely that either of these are achieveable).    46    
It is worth noting that the earliest retreatment was undertaken 
after 4 months.    3    
  Notwithstanding the above, the optimal treatment paradigm 
for rituximab has not been deﬁ   nitively determined. Options 
include treatment on ﬂ  are as practised in earlier RCT, regular 
re-treatment, for example, every 6 months, treatment with any 
deterioration or treatment-to-target. This is discussed in more 
detail in the supplementary material, available online only, with 
data from pooled phase II and III studies    69    as well as preliminary 
data from the German registry.    70    Retrospective data support in 
principle a treatment-to-target strategy, whereas regular re-treat-
ment may risk overtreatment in some patients. Of note, a lack 
on signs and symptoms as well as physical function in this pop-
ulation. The effect on structural damage was also evaluated in 
that trial (REFLEX), in which the 2×1000 mg dose was studied. 
Radiographic beneﬁ  t compared with placebo was demonstrated 
at 1 year    26    (but not at 24 weeks),    3        26    with recent data conﬁ  rming 
maintenance of retardation at 2 years.    27    
  Subsequent studies in all other RA populations, namely 
patients with previous inadequate response to traditional 
DMARD including methotrexate and patients naive to metho-
trexate, have also evaluated a lower dose of 500 mg per infu-
sion.    2        23       –       25    
  The SERENE    24    and MIRROR    23    studies both addressed metho-
trexate-inadequate responder patients and included two courses 
of 2×500 and 2×1000 mg 6 months apart; SERENE also had a pla-
cebo arm for comparison, while MIRROR adopted an additional 
dose escalation regimen—one course of 2×500 mg followed by 
a course of 2×1000 mg. ACR20, ACR50 and ACR70 response 
rates in patients treated with these rituximab doses were simi-
lar (as detailed in   table 4   and discussed further in the supple-
mentary material, available online only) (category Ib). Effects on 
joint damage were not assessed in this study. 
    In the IMAGE study in methotrexate-naive patients, the 2×500 
and 2×1000 mg dose groups were again compared.    25    The clini-
cal and functional outcomes were very similar. The higher dose 
(2×1000 mg) cohort demonstrated signiﬁ  cantly superior joint 
protection compared with placebo, while the lower dose (2×500 
mg) had numerical, although not statistical, radiographic ben-
eﬁ  t during the ﬁ  rst 24 weeks. Beyond this time point, however, 
(study duration of 2 years) radiographic progression was mini-
mal and indeed similar in both dose groups. These results are 
illustrated in the supplementary section available online only. 
  These data are important in expanding upon those observed 
in the previoius TNF inhibitor-experienced population from the 
REFLEX study described above. The optimal dose of rituximab 
thus remains insufﬁ  ciently deﬁ  ned, with considerable data sug-
gesting an overall equivalence of 2×500 mg with the licensed 
dose of 2×1000 mg for clinical efﬁ  cacy outcomes and medi-
um-term maintenance of radiographic non-progression. More 
research is required in this area. 
  In the phase II trial, the ACR responses of patients treated 
with rituximab in combination with methotrexate were 
numerically superior to those receiving rituximab monother-
apy (  table   ).    2    Rituximab monotherapy was also shown to be 
more effective than placebo only in ACR20 response but not in 
ACR50 and ACR70 responses    2    (category Ib). Rituximab is there-
fore only licensed in combination with methotrexate   (www.
accessdata.fda.gov/scripts/cder/drugsatfda  ,   www.ema.eu.int/
humans/Humans/EPAR/mabthera/mabthera  ). In clinical prac-
tice this will usually be a dose of 10–25 mg methotrexate per 
week, unless intolerance precludes such doses (category Ib). 
   Other  combinations 
  A number of abstracts (small observational studies and regis-
try data) have described the use of rituximab with DMARD 
other than methotrexate    31        66    (category III). They consistently 
demonstrate that leﬂ  unomide can be used safely and effectively 
as background DMARD therapy. The observational study, 
SUNDIAL, demonstrated the safety of rituximab on a variety 
of background non-biological DMARD and combinations    66    (cat-
egory III). An initial, relatively small randomised study (TAME) 
assessed rituximab on background etanercept or adalimumab 
and showed more infections with this combination    67    (category 
IIa); this approach should therefore be avoided. Data are available 
from the phase II trials on cyclophosphamide as co-medication,    1    
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autoimmune conditions. Data that have emerged from recent 
RCT are summarised in the supplementary material available 
online only. 
    CONTRAINDICATIONS  AND  AE 
  Contraindications 
  Contraindications to rituximab include hypersensitivity to 
rituximab or other murine proteins, active severe infections 
and severe heart failure (New York Heart Association class IV; 
  www.accessdata.fda.gov/scripts/cder/drugsatfda  ,   www.ema.
eu.int/humans/Humans/EPAR/mabthera/mabthera  ).    33      In non-
Hodgkin’s lymphoma, contraindications have been restricted to 
hypersensitivity to components of this product or murine pro-
teins. Patients with active infections (acute or chronic) should 
not be treated with rituximab. 
  Use  in  children 
  Safety and efﬁ  cacy in children with rheumatic diseases has not 
been established although an increasing number of case reports 
and series of successful rituximab usage are available in the 
literature.    86–92           
   Pregnancy 
  Rituximab treatment during pregnancy is contraindicated. A 
recent review93 of pregnancy outcomes from the rituximab 
global drug safety database identiﬁ  ed 231 cases of pregnancy 
associated with maternal rituximab exposure. Of 153 pregnan-
cies with known outcomes, 90 resulted in live births, 33 ended 
in spontaneous abortion, with one stillbirth at 20 weeks’ gesta-
tion (umbilical knot) and 28 elective terminations. Twenty-two 
of the live births were premature, with one neonatal death at 
6 weeks. Eleven infants had haematological abnormalities at 
birth; four neonatal infections and two congenital malforma-
tions were reported. A recent review of RA medications in 
pregnancy included B-cell levels during eight of these cases of 
rituximab exposure during pregnancy,    94    two cases were dur-
ing the ﬁ  rst trimester and were not associated with any B-cell 
depletion in the fetus; six cases in the second or third trimesters 
included three with similar rituximab levels to the mother with 
markedly reduced/undetectable B-cell numbers—spontaneous 
recovery was, however, observed within 6 months. IgG levels 
were tested and were normal in four out of the six cases and 
vaccination responses remained intact. The appropriate time 
interval between the last rituximab treatment and subsequent 
conception remains unclear. Although additional data are now 
becoming available, further data are required before safety rec-
ommendations for pregnancy can be produced; until that time 
contraception is recommended for 12 months after the last 
rituximab application in the label, and rituximab should also be 
avoided in lactating women (  www.accessdata.fda.gov/scripts/
cder/drugsatfda  ,   www.ema.eu.int/humans/Humans/EPAR/
mabthera/mabthera    ).    33    
    Adverse  events 
    Table 5   lists the more frequent (≥2%) AE recorded during the 
6-month placebo-controlled period from nine studies (IIa, IIb 
(DANCER), DANCER extension, REFLEX (and REFLEX exten-
sion), SERENE, MIRROR, SUNRISE and SIERRA studies);    18    data 
for the placebo and methotrexate group have been pooled from 
the phase IIa, IIb (DANCER), REFLEX and SERENE studies. 
   Infusion-related  reactions 
  The tolerability and safety of rituximab has been well described 
in clinical trials on patients with RA and review articles on 
of long-term safety data relating to different dosing regimens 
in the re-treatment of RA means it is important that caution is 
exercised if or when patients are being regularly re-treated. 
   Managing  non-response 
  Several studies have reported the outcome of re-treating ritux-
imab non-responders with a further cycle. Several of these (with, 
in one study, 95% of non-responders showing poor early periph-
eral blood B-cell depletion using a high sensitivity assay)    71    dem-
onstrate that seropositive patients who fail to respond to a ﬁ  rst 
course of rituximab may respond to a second course    23 24        36        66        70 71           
(accompanied by more complete B-cell depletion).    71    A couple of 
other studies, however, suggest little improvement to be gained 
with re-treatment.    36        72    In light of the availability of other thera-
peutic options, for individual (particularly seronegative) patients 
who are rituximab non-responders or insufﬁ  cient responders, 
other treatment options should be considered depending on pre-
vious drug history. 
        Post-TNF inhibitor failure and biological DMARD therapy 
after rituximab 
  Post-TNF  inhibitor  failure 
  A few observational, registry-based and single-centre studies 
have compared the use of rituximab in TNF inhibitor inade-
quate responders versus switching to another TNF inhibitor    73–77           
(discussed in the supplementary material, available online only). 
There has been no head-to-head comparison to date, with a 
recent meta-analysis conﬁ  rming similar clinical beneﬁ  ts from 
these RCT;    78    associated management recommendations did not 
establish a preference for a particular biological agent in this 
situation.    47    
      Safety of other biological DMARD post-rituximab 
  Switching from rituximab to a TNF inhibitor has been associated 
with a numerically, but not statistically, signiﬁ  cant increase in 
serious infections in an early study;    79    a subsequent report provid-
ing further follow-up of the same cohort did not suggest a major 
increase in infections under these circumstances.    80    In this latter 
report TNF inhibitors were usually initiated at least 4 months 
after rituximab (when insufﬁ  cient treatment response would be 
judged). No signiﬁ  cant increase in serious infections was noted 
compared with the incidence before the new biological DMARD 
(TNF inhibitors in the majority of cases), with similar rates to a 
biological DMARD-naive group commenced on a TNF inhibitor; 
however, a wide interval from rituximab exposure to subsequent 
biological DMARD exposure was present (0.5–37 months) with 
a small sample size.    80    Data from the French Autoimmunity and 
Rituximab and Orencia in Rheumatoid Arthritis registries indicate 
that previous use of rituximab followed by treatment with abata-
cept does not increase the short-term risk of severe infection.    81    
These are preliminary reports and clearly further data on the 
safety of using other biological DMARD before or after rituximab 
need to be established. 
    Cost-effectiveness 
  Rituximab has been evaluated as a cost-effective treatment    82    
with three studies comparing rituximab with TNF inhibitor    83–85           
following TNF inhibitor failure; the methods differed slightly but 
all suggested equivalent/favourable results towards rituximab. 
      Role of rituximab in other autoimmune diseases 
  In addition to RA, accumulating evidence suggests rituximab 
could also be an effective treatment option in the management 
of patients with vasculitis, connective tissue diseases and other 
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antihistamines, bronchodilators, eventually glucocorticoids). 
Severe infusion reactions leading to drug discontinuation are 
uncommon (<1%) and are mainly restricted to the ﬁ  rst infu-
sion (Roche data on ﬁ  le). Their frequency is reduced by the 
use of concomitant intravenous steroids    1       –       3    (category Ia;   www.
accessdata.fda.gov/scripts/cder/drugsatfda  ,   www.ema.eu.int/
humans/Humans/EPAR/mabthera/mabthera    ).    33    There have 
been several reports from haematology experience on the safety 
of shortened (60–90 min) infusion times.    95       –       99    
  In the context of glucocorticoid use with rituximab, AE due to 
glucocorticoids also need to be considered. 
   Serious  infections 
  Rituximab does not seem to increase the risk of infections in 
patients with HIV with lymphoma    62        100    (category IIb). In the 
oncology literature, rituximab does not markedly add to the 
risk of infections induced by chemotherapy; this includes 
opportunistic infections    62    and also herpes zoster infections, 
although there was one case of disseminated and fatal herpes 
zoster infection.    62        101    In the long-term safety analysis of RA 
trials    18    herpes zoster occurred in 2% of patients (n=49; 0.98 
events/100 patient-years) with only one case a serious AE; this 
rate appears to be similar to the rate seen with TNF inhibitors 
(1.11 events/100 patient-years).    102    
  In two clinical trials carried out on patients with RA,    2        3    a 
numerically higher rate of serious infections (but not opportu-
nistic infections, including tuberculosis) was seen in patients 
receiving rituximab at 2×1000 mg compared with those receiv-
ing placebo: 4.7 versus 3.2/100 patient-years in the DANCER 
study and 5.2 versus 3.7/100 patient-years in the REFLEX 
study    2        3    (category III). In the recent IMAGE study in metho-
trexate-naive patients, however, serious infections were lower 
in the two rituximab dosage groups (1000 and 500 mg) com-
pared with placebo (3.74, 4.61 and 6.09 events/100 patient-
years, respectively).    25    A recent meta-analysis included three 
  Table  5         AE occurring during the 6-month placebo-controlled period of 
nine  studies       18     
 
 Placebo+MTX 
(n=570) 
 Rituximab+MTX 
(n=877) 
Total patients (%) with ≥1 AE infection 223 (39.1) 353 (40.3)
  Infections occurring in ≥2% of patients
  Nasopharyngitis  43  (7.5)  63  (7.2)
  Upper respiratory tract infections*   37 (6.5)   64 (7.3)
  Urinary tract infection*   31 (5.4)   31 (3.5)
  Bronchitis*  19  (3.3)  27  (3.1)
  Sinusitis  20  (3.5)  25  (2.9)
  Gastroenteritis  14  (2.5)  12  (1.4)
  Pharyngitis  12  (2.1)  11  (1.3)
Total patients (%) with a serious infection     9 (1.6)   15 (1.7)
  Pneumonia   2  (0.4)   2  (0.2)
  Gastroenteritis   2  (0.4)   1  (0.1)
  Pyelonephritis 0   3  (0.3)
  Respiratory  tract  infection   2  (0.4)   0
  Abscess  bacterial   1  (0.2)   0
  Abscess  intestinal   1  (0.2)   0
  Bronchitis 0   1  (0.1)
  Bronchopneumonia   1  (0.2)   0
  Cellulitis 0   1  (0.1)
 Cellulitis  gangrenous 0   1  (0.1)
      Infusion-related reactions were the most common adverse event (AE) (25% infusion 1). 
Data for the placebo + methotrexate (MTX) group pooled from trials IIa, DANCER, 
REFLEX and SERENE. The overall rate (95% CI) of AE was 359.6 events per 100 patient-
years (354.4 to 364.9) with highest rates during course 1; for serious AE, the rate (95% 
CI) was 17.85 events per 100 patient-years (16.72 to 19.06). 
 *Occurred  in  ≥10%  patients.   
  Table  6         Summary of additional clinical and research aspects for future consideration   
Future clinical and research agenda
Safety Rituximab in the context of concomitant
  Milder congestive heart failure (NYHA I–III)
  Demyelinating disorders (efﬁ  cacy seen in phase I–II studies of MS/NMO)
 New-onset  malignancy
Registry data
 tuberculosis  reactivation
  Rare serious AE (PML)
  Parameters associated with infection risk (Ig)
  Vaccination—minimal interval between vaccine and RTX administration
Efﬁ  cacy
  Disease groups Connective tissue disorders
RA/vasculitis; overlap syndromes
  Dosage regimen Dose, dosage schedule
Different induction and maintenance regimens?
Impact of different dosage regimens on structural progression
  Concomitant medication Alternative DMARD to MTX
Timing and initiation of DMARD
Combination RTX with other biological agent
  Flare and retreatment Early signs of ﬂ  are/reactivation
Long-term impact of re-treatment/repeat multiple cycles
  Translational research Mechanism of action of RTX
Biomarkers of response
Indicators of re-treatment (B cell/subsets)
Switching biological therapies Merit of RTX following initial TNF-i failure compared to alternative TNF-i or other biological agent
Pharmacoeconomic analyses
      DMARD, disease-modifying antirheumatic drug; MS, multiple sclerosis; MTX, methotrexate; NMO, neuromyelitis optica; NYHA, New 
York Heart Association; PML, progressive multifocal leukoencephalopathy; RA, rheumatoid arthritis; RTX, rituximab; TB, tuberculosis; 
TNF-i, tumour necrosis factor inhibitor.     
  non-Hodgkin’s lymphoma    62    (category III)    1        2        18    (category Ia). 
The most frequent AE are infusion reactions (30–35% with the 
ﬁ   rst infusion with concomitant glucocorticoids). Fewer reac-
tions are observed with the second and subsequent infusions    1       –       3    
    18    (category Ia). They are usually mild to moderate, but may 
require therapeutic intervention (additional paracetamol, 
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  Box 1  Points to consider for treatment with rituximab   
       Indication       
  RA with inadequate response to (or intolerance of) TNF inhibitors 
             Active RA (at least moderate disease activity) 
             Possibly: RA with contraindication to TNF inhibitors (especially lymphoma) and inadequate response to disease-modifying antirheu-
matic drugs such as methotrexate, particularly given new data on methotrexate-inadequate responder and naive patient groups 
      Contraindications 
        Allergy  to  rituximab 
           Clinically relevant comorbidities, including active infections and severe heart failure (New York Heart Association class IV) 
        Pregnancy 
      Pretreatment  screening 
        History  and  physical  examination 
          Consider  possible  contraindications 
             Consider radiograph of the chest 
        Routine  laboratory  testing 
        Immunoglobulin  levels 
           Testing for hepatitis B; consider testing for hepatitis C 
        Assess  necessity  of  vaccination 
      Treatment  dose  and  co-medication 
           Two 1000 mg intravenous infusions separated by 2 weeks (licensed regimen in TNF inhibitor failures) 
             Two 500 mg intravenous infusions separated by 2 weeks have similar clinical, functional and long-term radiographic efﬁ  cacy (studied in 
all populations except TNF inhibitor failures) 
             100 mg intravenous methylprednisolone or equivalent before infusions 
           Weekly methotrexate to increase efﬁ  cacy (if tolerated) 
             Other DMARD (especially leﬂ  unomide) may be used as an alternative 
         Evaluation and deﬁ  nition of response 
           Validated composite indices to assess response 
           Minimum improvement of DAS28 of 1.2 or greater or equivalent measure 
               Aim for remission (DAS28 <2.6, SDAI ≤3.3 or CDAI ≤2.8) or low disease activity state (DAS28 ≤3.2, simpliﬁ  ed disease activity 
index (SDAI) ≤11, clinical disease activity index (CDAI) ≤10) 
             Aim for improvement in function and quality of life; minimum response is usually achieved in 16 weeks 
      Repeated  treatment 
           Should be considered in responders after week 16 
             Residual active disease (at least low disease activity state, ie, DAS28 ≥>2.6, SDAI >>3.3, CDAI >>2.8) 
             Reactivation of disease from low disease activity state (increase in DAS28 of >0.6 or equivalent) 
      Adverse  events 
           Infusion reactions (30–35% after the ﬁ  rst infusion; less with the second infusion) 
             Severe infusion reactions may occur but are rare 
           Slight increase in infections compared with placebo population, especially in patients with low IgG 
             Cases of PML have been reported (~1:20 000)     
RCT and did not observe an increased risk of severe infections 
in RA patients treated with rituximab compared with place-
bo.    103    Registry data have suggested that serious infections tend 
to occur in the initial months following rituximab, with pre-
disposing factors comprising age, comorbidity, extra-articular 
involvement and low IgG.    30    
  Hepatitis B reactivation has been widely documented in the 
oncology literature60 62 highlighting the need to pre-screen 
patients (see the earlier section on ‘Screening before initiating 
rituximab’ with additional information provided in the supple-
mentary material, available online only). Clinical trials in RA 
pre-screened patients for hepatitis B and C. Only one case of 
hepatitis B reactivation in a patient with RA has been report-
ed.52 Although the risk of hepatitis C virus is not as clear54 we 
would also recommend pre-screening. Management in consulta-
tion with an expert gastroenterologist/hepatologist is advised.
In the clinical trial safety database, two cases of pulmonary 
tuberculosis have been reported; these appear to have been de 
novo infections (information from Roche). Among patients with 
RA, three cases of tuberculosis and ﬁ  ve cases with non-tuber-
culous mycobacterial infections haven been reported through a 
survey carried out in the USA and Canada.    104    However, patients 
with records of tuberculosis have been treated with rituximab 
without any tuberculosis reactivation.    30    
  In RA, six cases with progressive multifocal leukoencephal-
opathy (PML) have been reported (Roche data on ﬁ  le), includ-
ing one case from the REFLEX trial    3    giving an incidence of less 
than 1:20 000 treated RA patients, compared with PML risks 
for patients with psoriasis treated with efalizumab (1:400) and 
patients with Crohn’s disease and multiple sclerosis treated with 
natalizumab (1:1000).    105        106    Most PML cases with RA had long-
standing disease with numerous previous immunosuppressive 
treatments; only one patient had early RA naive to methotrexate 
and other DMARD. Currently, there is no identiﬁ  ed risk proﬁ  le 
for developing PML. Although the risk seems small, at this stage 
we would still advise clinicians to maintain vigilance. Additional 
background information on PML is provided in the supplemen-
tary material, available online only. 
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AE and serious events including infections and serious infections 
remained stable across several courses. 
     ADDITIONAL  ASPECTS  TO  BE  CONSIDERED  AND 
RESEARCH AGENDA 
  It is evident from this document that several areas of future inves-
tigation and research are warranted. These are summarised in 
  table 6   but are discussed in detail in the supplementary material, 
available online only. These relate particularly to mode of action, 
safety and efﬁ  cacy issues; with respect to the latter, questions 
such as optimal dose regimen, direct comparison with other bio-
logical agents and indicators for retreatment require appropriate 
answers. 
    CONCLUSION 
  Additional data on rituximab in the management of RA have 
accumulated since publication of the ﬁ  rst consensus statement 
and have provided further insights into its use (  box 1  ). Beneﬁ  t in 
earlier disease has been demonstrated together with novel radio-
graphic information. It is now also ﬁ  rmly established that ritux-
imab is effective primarily in seropositive RA. Recent studies have 
further supported the efﬁ  cacy of reduced dosage and different 
regimens, although more work is needed to establish the optimal 
strategy. Safety data from rheumatology as well as oncology liter-
ature highlight the need for hepatitis screening as well as checking 
pretreatment immunoglobulin levels to identify patients possibly 
at greater risk of infection. Data thus far do not indicate the need 
for routine tuberculosis screening. As with other biological agents, 
the need for vaccination should be assessed. Safety concerns for 
very rare events such as PML have emerged. Ongoing evaluations 
should clarify the remaining open issues and ultimately lead to a 
more reﬁ  ned application of rituximab therapy. 
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      Immunoglobulin levels and infection risk 
  The literature on patients with RA treated with rituximab 
describes low baseline levels of IgG, including before rituximab 
administration, as being associated with an increased risk of 
serious infections—these data come from a registry (hypo-IgG 
being present at baseline before rituximab in 5% of patients) 
as well as from compiled data from clinical trials.    18        30    In open 
extension studies, the occurrence of IgG levels below the lower 
limit of normal under rituximab treatment, especially sustained 
(≥4 month) IgG below the lower limit, was associated with an 
increased risk of serious infections    18    (data provided by Roche). 
In general, in addition to more traditional risk factors for infec-
tion such as age and concomitant glucocorticoid, patients with 
low IgG levels particularly need careful observation. Better 
deﬁ  nition and clarity on the management of low level IgG is 
still needed; nevertheless, from the data summarised to date, 
as recommended earlier, IgG should be monitored in patients 
treated with rituximab, particularly in those who demonstrate 
low baseline levels, with close monitoring particularly in higher-
risk patient groups such as the older patient. The more frequent 
decreases in IgM, in contrast, have not been associated with 
increased rates of infections. After 1 year of treatment, levels of 
IgM were lower in patients receiving 2×1000 mg versus those 
receiving 2×500 mg (unpublished Roche data). 
   Malignancy  risk 
  Although patients with previous malignancy are usually 
excluded in clinical trials; so far, no enhanced rates of solid 
malignancies or lymphoma under rituximab treatment have 
been observed    18        62    (category Ia)    107    (category III), with the 
exception of individuals with T-cell deﬁ  ciency in HIV infec-
tion    108    (category III). Therefore, to date, there have been no 
safety signals regarding malignancies; however, with respect to 
RA, larger databases on safety data are required before any ﬁ  rm 
conclusions can be drawn. 
   Haematological  side-effects 
  In the oncology literature, late-onset neutrocytopaenia has 
been reported in up to 8% of patients treated with rituximab 
monotherapy and combination treatment and may occur up 
to 1 year after treatment    62    (category Ia)    100        109       –       112    (category III). 
For unknown reasons, this complication is very rare in patients 
treated for autoimmune diseases. In some patients treatment 
with granulocyte colony-stimulating factor has been required. A 
multifactorial aetiology is likely to underlie the blood dyscrasia. 
   Human  antichimeric  antibodies 
  As rituximab is a chimeric antibody, human antichimeric anti-
bodies (HACA) may occur. In the long-term, pooled safety anal-
ysis, 11% (273/2578 patients) were HACA positive on at least 
one visit.    18    The rate of infusion reaction with re-treatment was 
similar in the HACA-positive compared with HACA-negative 
patients. AE related to HACA are rare, but a case of a severe 
allergic reaction was reported in which HACA apparently 
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